{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005872","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.852918+00:00","generated_at":"2026-06-19T02:19:42.475905+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"INVO Bioscience issues $200K convertible debenture at 8% interest, with warrants and commitment shares","bullets":["Issued $200,000 convertible debenture to Firstfire Global Opportunities Fund at $180,000 purchase price (10% OID).","Debenture carries 8% annual interest, matures Feb 17, 2024; convertible at $0.52 per share initially.","Also issued warrant to buy 100,000 shares at $0.75 and 33,333 commitment shares as inducement.","Proceeds used for working capital; placement agent fee $14,400.","Exchange cap of 2,436,045 shares (19.99% of outstanding) unless shareholder approval obtained."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005872","json":"https://secwatch.observer/filing/0001493152-23-005872.json","markdown":"https://secwatch.observer/filing/0001493152-23-005872.md","text":"https://secwatch.observer/filing/0001493152-23-005872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223005872/0001493152-23-005872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223005872/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:19:42.475905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba8baec3bff16ca99e6e303736e4f9636d4daad3","claim":"INVO Fertility, Inc. incurred convertible notes of $200,000 with Firstfire Global Opportunities Fund, LLC at 8% per annum maturing February 17, 2024.","evidence_excerpt":"On February 17 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Firstfire Global Opportunities Fund, LLC, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $200,000","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223005872/0001493152-23-005872-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$200,000"},{"label":"Counterparty","value":"Firstfire Global Opportunities Fund, LLC"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"February 17, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"c2c9fbf0d65f9db5529b146c135aeec9c7dfc252","claim":"INVO Fertility, Inc. entered into Purchase Agreement with Firstfire Global Opportunities Fund, LLC valued at $200,000 (effective 2023-02-17).","evidence_excerpt":"On February 17 2023 (the “Closing”), INVO Bioscience, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Firstfire Global Opportunities Fund, LLC, an accredited investor (the “Buyer”) for the purchase of (i) a convertible debenture of the Company (the “Debenture”) in the aggregate original principal amount of $200,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223005872/0001493152-23-005872-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Firstfire Global Opportunities Fund, LLC"},{"label":"Value","value":"$200,000"},{"label":"Effective","value":"2023-02-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}